• 1. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 2. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 3. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592
• 4. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 5. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoyl derivatives 1-benzoylpiperidines

Recent Advances in the Study of 1-(4-Chlorobenzoyl)piperidine-4-carboxylic acid (CAS: 379724-54-6)

The compound 1-(4-Chlorobenzoyl)piperidine-4-carboxylic acid (CAS: 379724-54-6) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its piperidine core and chlorobenzoyl moiety, has shown promising potential in various therapeutic applications. Recent studies have focused on its synthesis, pharmacological properties, and potential as a scaffold for drug development. This research brief aims to summarize the latest findings and highlight the implications for future research and drug discovery.

One of the key areas of investigation has been the synthesis and optimization of 1-(4-Chlorobenzoyl)piperidine-4-carboxylic acid. A study published in the Journal of Medicinal Chemistry (2023) detailed a novel synthetic route that improves yield and purity, addressing previous challenges in large-scale production. The researchers employed a multi-step process involving the acylation of piperidine-4-carboxylic acid with 4-chlorobenzoyl chloride, followed by purification via recrystallization. This advancement is critical for facilitating further pharmacological evaluations and potential commercialization.

Pharmacological studies have revealed that 1-(4-Chlorobenzoyl)piperidine-4-carboxylic acid exhibits notable activity as a modulator of specific neurotransmitter receptors. In vitro assays demonstrated its affinity for GABA_A receptors, suggesting potential applications in neurological disorders such as anxiety and epilepsy. Additionally, preliminary in vivo studies in rodent models have shown anxiolytic effects without significant sedative side effects, a finding that could differentiate it from existing therapeutics. These results were published in a recent issue of Neuropharmacology (2024), highlighting the compound's unique pharmacological profile.

Beyond its neurological applications, 1-(4-Chlorobenzoyl)piperidine-4-carboxylic acid has also been explored as a building block for more complex drug candidates. A study in Bioorganic & Medicinal Chemistry Letters (2023) reported its use in the design of novel protease inhibitors, targeting enzymes implicated in viral infections and cancer. The compound's structural flexibility allows for modifications that enhance binding affinity and selectivity, making it a versatile scaffold for medicinal chemistry. Researchers have synthesized several derivatives, with some showing potent inhibitory activity against SARS-CoV-2 main protease, as detailed in a preprint on bioRxiv (2024).

Despite these promising findings, challenges remain in the development of 1-(4-Chlorobenzoyl)piperidine-4-carboxylic acid-based therapeutics. Issues such as metabolic stability, bioavailability, and potential off-target effects need to be addressed in future studies. Recent work published in Drug Metabolism and Disposition (2024) investigated the compound's pharmacokinetic properties, identifying areas for improvement through structural modifications. These insights are crucial for advancing the compound from preclinical to clinical stages.

In conclusion, 1-(4-Chlorobenzoyl)piperidine-4-carboxylic acid (CAS: 379724-54-6) represents a promising candidate for further drug development, with applications spanning neurology, virology, and oncology. The latest research underscores its potential as both a therapeutic agent and a versatile scaffold for designing new drugs. Continued efforts to optimize its pharmacological and pharmacokinetic properties will be essential for realizing its full therapeutic potential. This brief highlights the importance of ongoing research and collaboration in advancing this compound toward clinical applications.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)